bioRxivCancer Biology
Expressed barcodes enable clonal characterization of chemotherapeutic responses in chronic lymphocytic leukemia
A. Al'Khafaji, C. Gutierrez, E. Brenner, R. Durrett, K. E. Johnson, W. Zhang, S. Li, K. J. Livak, D. Neuberg, A. Brock, C. J. Wu
Abstract
The remarkable evolutionary capacity of cancer is a major challenge to current therapeutic efforts. Fueling this evolution is its vast clonal heterogeneity and ability to adapt to diverse selective pressures. Although the genetic and transcriptional mechanisms underlying these responses have been independently evaluated, the ability to couple genetic alterations present within individual clones to their respective transcriptional or functional outputs has been lacking in the field. To this end, we developed a high-complexity expressed barcode library that integrates DNA barcoding with single-cell RNA sequencing through use of the CROP-seq sgRNA expression/capture system, and which is compatible with the COLBERT clonal isolation workflow for subsequent genomic and epigenomic characterization of specific clones of interest. We applied this approach to study chronic lymphocytic leukemia (CLL), a mature B cell malignancy notable for its genetic and transcriptomic heterogeneity and variable disease course. Here, we demonstrate the clonal composition and gene expression states of HG3, a CLL cell line harboring the common alteration del(13q), in response to front-line cytotoxic therapy of fludarabine and mafosfamide (an analog of the clinically used cyclophosphamide). Analysis of clonal abundance and clonally-resolved single-cell RNA sequencing revealed that only a small fraction of clones consistently survived therapy. These rare highly drug tolerant clones comprise 94% of the post-treatment population and share a stable, pre-existing gene expression state characterized by upregulation of CXCR4 and WNT signaling and a number of DNA damage and cell survival genes. Taken together, these data demonstrate at unprecedented resolution the diverse clonal characteristics and therapeutic responses of a heterogeneous cancer cell population. Further, this approach provides a template for the high-resolution study of thousands of clones and the respective gene expression states underlying their response to therapy.
- organism: human
- assay: scRNA-seq
- research focus: clustering
- research focus: differential expression
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Clonal differences underlie variable responses to sequential and prolonged treatment
Dylan L. Schaff, Aria J. Fasse, … Sydney M. Shaffer·Cell SystemsPeer-reviewed·Feb 23, 2024
- Chemotherapy reshapes cellular clonal landscape via persister programs in breast cancer xenografts
Sarah Kronheim, J C M Wang, … Long V. Nguyen·bioRxiv·Apr 6, 2026
- Prediction of therapy outcomes of CLL using gene expression intensity, clustering, and ANN classification of single cell transcriptomes
Minjie Lyu, Huan Jin, … Vladimir Brusić·bioRxiv·Aug 8, 2021
- Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia
A. F. Rendeiro, T. Krausgruber, … C. Bock·bioRxiv·Apr 3, 2019
- Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL
P.-M. Bruch, H. A. R. Giles, … S. Dietrich·bioRxiv·Jul 23, 2021
- Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia
Gage S. Black, Xiaomeng Huang, … Gábor Marth·Genome ResearchPeer-reviewed·Apr 1, 2025